AstraZeneca PLC (ETR:ZEG)

AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of EUR 227.45 billion. The enterprise value is 248.23 billion.

Market Cap	227.45B
Enterprise Value	248.23B

Important Dates

The last earnings date was Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	Aug 7, 2025

Share Statistics

Current Share Class	1.55B
Shares Outstanding	n/a
Shares Change (YoY)	-0.08%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	80.50%
Float	1.54B

Valuation Ratios

The trailing PE ratio is 28.39 and the forward PE ratio is 16.93.

PE Ratio	28.39
Forward PE	16.93
PS Ratio	4.59
PB Ratio	5.81
P/TBV Ratio	n/a
P/FCF Ratio	21.08
P/OCF Ratio	17.63
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.14, with an EV/FCF ratio of 23.01.

EV / Earnings	30.99
EV / Sales	5.05
EV / EBITDA	14.14
EV / EBIT	18.46
EV / FCF	23.01

Financial Position

The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.71.

Current Ratio	0.88
Quick Ratio	0.69
Debt / Equity	0.71
Debt / EBITDA	1.57
Debt / FCF	2.58
Interest Coverage	12.24

Financial Efficiency

Return on equity (ROE) is 21.67% and return on invested capital (ROIC) is 13.17%.

Return on Equity (ROE)	21.67%
Return on Assets (ROA)	9.07%
Return on Invested Capital (ROIC)	13.17%
Return on Capital Employed (ROCE)	19.79%
Revenue Per Employee	525,362
Profits Per Employee	84,950
Employee Count	94,300
Asset Turnover	0.53
Inventory Turnover	1.59

Taxes

In the past 12 months, AstraZeneca has paid 1.73 billion in taxes.

Income Tax	1.73B
Effective Tax Rate	17.79%

Stock Price Statistics

The stock price has increased by +22.29% in the last 52 weeks. The beta is 0.17, so AstraZeneca's price volatility has been lower than the market average.

Beta (5Y)	0.17
52-Week Price Change	+22.29%
50-Day Moving Average	139.59
200-Day Moving Average	132.21
Relative Strength Index (RSI)	62.80
Average Volume (20 Days)	12,425

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of EUR 49.54 billion and earned 8.01 billion in profits. Earnings per share was 5.13.

Revenue	49.54B
Gross Profit	41.25B
Operating Income	13.56B
Pretax Income	9.75B
Net Income	8.01B
EBITDA	17.41B
EBIT	13.56B
Earnings Per Share (EPS)	5.13

Balance Sheet

The company has 6.97 billion in cash and 27.84 billion in debt, giving a net cash position of -20.86 billion.

Cash & Cash Equivalents	6.97B
Total Debt	27.84B
Net Cash	-20.86B
Net Cash Per Share	n/a
Equity (Book Value)	39.18B
Book Value Per Share	25.22
Working Capital	-3.51B

Cash Flow

In the last 12 months, operating cash flow was 12.90 billion and capital expenditures -2.12 billion, giving a free cash flow of 10.79 billion.

Operating Cash Flow	12.90B
Capital Expenditures	-2.12B
Free Cash Flow	10.79B
FCF Per Share	n/a

Margins

Gross margin is 83.26%, with operating and profit margins of 27.38% and 16.17%.

Gross Margin	83.26%
Operating Margin	27.38%
Pretax Margin	19.68%
Profit Margin	16.17%
EBITDA Margin	35.13%
EBIT Margin	27.38%
FCF Margin	21.78%

Dividends & Yields

This stock pays an annual dividend of 2.91, which amounts to a dividend yield of 1.99%.

Dividend Per Share	2.91
Dividend Yield	1.99%
Dividend Growth (YoY)	6.78%
Years of Dividend Growth	3
Payout Ratio	52.89%
Buyback Yield	0.08%
Shareholder Yield	2.07%
Earnings Yield	3.52%
FCF Yield	4.74%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.98
Piotroski F-Score	7